2020
Decline in renal function and oral anticoagulation dose reduction among patients with atrial fibrillation
Inohara T, Holmes DN, Pieper K, Blanco RG, Allen LA, Fonarow GC, Gersh BJ, Hylek EM, Ezekowitz MD, Kowey PR, Reiffel JA, Naccarelli GV, Chan PS, Mahaffey KW, Singer DE, Freeman JV, Steinberg BA, Peterson ED, Piccini JP. Decline in renal function and oral anticoagulation dose reduction among patients with atrial fibrillation. Heart 2020, 106: heartjnl-2019-315792. PMID: 31911503, DOI: 10.1136/heartjnl-2019-315792.Peer-Reviewed Original ResearchConceptsAtrial fibrillationRenal functionOral anticoagulationDose reductionAtrial Fibrillation II registryBetter Informed TreatmentML/minCrCl declineOral anticoagulantsCreatinine clearanceOutcomes RegistryGuideline criteriaPatientsPackage insertsUS FoodDrug AdministrationMean declineInformed TreatmentNOACsAnticoagulationFibrillationRegistryDosingCrClOne-fourth
2018
Frequency and Outcomes of Reduced Dose Non–Vitamin K Antagonist Anticoagulants: Results From ORBIT‐AF II (The Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II)
Steinberg BA, Shrader P, Pieper K, Thomas L, Allen LA, Ansell J, Chan PS, Ezekowitz MD, Fonarow GC, Freeman JV, Gersh BJ, Kowey PR, Mahaffey KW, Naccarelli GV, Reiffel JA, Singer DE, Peterson ED, Piccini JP, Investigators T. Frequency and Outcomes of Reduced Dose Non–Vitamin K Antagonist Anticoagulants: Results From ORBIT‐AF II (The Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II). Journal Of The American Heart Association 2018, 7: e007633. PMID: 29453305, PMCID: PMC5850192, DOI: 10.1161/jaha.117.007633.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAgedAged, 80 and overAnticoagulantsAtrial FibrillationDrug Dosage CalculationsDrug PrescriptionsFemaleGuideline AdherenceHemorrhageHumansMaleMiddle AgedPractice Guidelines as TopicPractice Patterns, Physicians'Prospective StudiesRegistriesStrokeTime FactorsTreatment OutcomeUnited StatesConceptsDrug Administration labelingAtrial fibrillationNOAC doseAF patientsDose reductionNon-vitamin K antagonist anticoagulantsUS FoodORBIT-AF II registryInappropriate dose reductionOutcomes of patientsHigher unadjusted ratesCommunity practiceDrug Administration recommendationsNOAC dosesStandard dosingObservational registryOral anticoagulantsStroke preventionThromboembolic eventsUnadjusted ratesCertain patientsStandard doseNOACsPatterns of useRisk score